{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T01:07:23Z","timestamp":1794791243317,"version":"4.9.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-11A1-CG-CO-04-2225-1"],"award-info":[{"award-number":["NHRI-11A1-CG-CO-04-2225-1"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-12A1-CG-CO-04-2225-1"],"award-info":[{"award-number":["NHRI-12A1-CG-CO-04-2225-1"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-13A1-CG-CO-04-2225-1"],"award-info":[{"award-number":["NHRI-13A1-CG-CO-04-2225-1"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-14A1-CG-CO-04\u20132225-1"],"award-info":[{"award-number":["NHRI-14A1-CG-CO-04\u20132225-1"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"NSTC","doi-asserted-by":"publisher","award":["112-2628-B-006-003-"],"award-info":[{"award-number":["112-2628-B-006-003-"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"NSTC","doi-asserted-by":"publisher","award":["NSTC 113-2628-B-006-009-"],"award-info":[{"award-number":["NSTC 113-2628-B-006-009-"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Edward Chia-Cheng Lai"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We evaluated drug retention rates to compare the effectiveness of Janus kinase (JAK) inhibitors vs TNF inhibitor (TNFi) biologics and non-TNFi biologics in biologics-na\u00efve RA patients, and assessed intra-class differences among JAK inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a cohort study using Taiwan\u2019s National Health Insurance Research Database, including RA patients initiating TNFi biologics, non-TNFi biologics or JAK inhibitors. We followed patients from index date until outcome, death or end of 2-year study period. To evaluate retention rate, we used treatment change defined as discontinuation or switching of medications. We calculated hazard ratios of treatment change to compare the effectiveness of JAK inhibitors vs biologics, using JAK inhibitors as reference group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 16\u2009212 patients, 2654 (16.37%) received JAK inhibitors, 10\u2009080 (62.18%) received TNFi biologics, and 3478 (21.45%) received non-TNFi biologics. We found TNFi biologics were associated with a higher risk of treatment change than JAK inhibitors (hazard ratio\u2009=\u20091.38; 95% CI: 1.25\u20131.53). We found no significant difference between JAK inhibitors and non-TNFi biologics. The risk of treatment change among JAK inhibitors (tofacitinib, baricitinib) was similar.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our findings reflected drug effectiveness by the duration that patients maintained the regimen, considering both therapeutic effects and adverse events. We found JAK inhibitors had better effectiveness than TNFi biologics, with no significant difference compared with non-TNFi biologics in biologics-na\u00efve patients. Intra-class comparison of JAK inhibitors indicated similar effectiveness for both tofacitinib and baricitinib. These findings supported the use of JAK inhibitors in RA patients after failure of conventional DMARDs treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf216","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T08:09:49Z","timestamp":1744963789000},"page":"4668-4677","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of JAK inhibitors in biologics-na\u00efve patients with RA: a population-based study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1738-9671","authenticated-orcid":false,"given":"Albert Tzu-Ming","family":"Chuang","sequence":"first","affiliation":[{"name":"Population Health Data Center, National Cheng Kung University , Tainan,","place":["Taiwan"]},{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-0338","authenticated-orcid":false,"given":"Daniel Hsiang-Te","family":"Tsai","sequence":"additional","affiliation":[{"name":"Population Health Data Center, National Cheng Kung University , Tainan,","place":["Taiwan"]},{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-2134","authenticated-orcid":false,"given":"Meng-Yu","family":"Weng","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, National Cheng-Kung University Medical Center , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-653X","authenticated-orcid":false,"given":"Huei-Kai","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Hualien,","place":["Taiwan"]},{"name":"Center for Clinical Epidemiology and Biostatistics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Hualien,","place":["Taiwan"]},{"name":"School of Medicine, Tzu Chi University , Hualien,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-7652","authenticated-orcid":false,"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Population Health Data Center, National Cheng Kung University , Tainan,","place":["Taiwan"]},{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"2025080115380164900_keaf216-B1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025080115380164900_keaf216-B2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025080115380164900_keaf216-B3","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2025080115380164900_keaf216-B4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study","volume":"76","author":"Keystone","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025080115380164900_keaf216-B5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/jcm8060831","article-title":"Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial","volume":"8","author":"Taylor","year":"2019","journal-title":"J Clin Med"},{"key":"2025080115380164900_keaf216-B6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0950-3579(05)80305-X","article-title":"The epidemiology of drug treatment failure in rheumatoid arthritis","volume":"9","author":"Wolfe","year":"1995","journal-title":"Baillieres Clin Rheumatol"},{"key":"2025080115380164900_keaf216-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2015.171","article-title":"Drug survival studies in dermatology: principles, purposes, and pitfalls","volume":"135","author":"van den Reek","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2025080115380164900_keaf216-B8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/ard-2023-224670","article-title":"Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study)","volume":"83","author":"Aymon","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025080115380164900_keaf216-B9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003160","article-title":"Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"9","author":"Ebina","year":"2023","journal-title":"RMD Open"},{"key":"2025080115380164900_keaf216-B10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025080115380164900_keaf216-B11","doi-asserted-by":"crossref","first-page":"e001174","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"2025080115380164900_keaf216-B12","doi-asserted-by":"crossref","first-page":"152314","DOI":"10.1016\/j.semarthrit.2023.152314","article-title":"Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study","volume":"64","author":"Scheepers","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025080115380164900_keaf216-B13","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/rheumatology\/keac068","article-title":"Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data","volume":"61","author":"Barbulescu","year":"2022","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025080115380164900_keaf216-B14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2169\/internalmedicine.9341-17","article-title":"Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-na\u00efve and experienced patients","volume":"57","author":"Mori","year":"2018","journal-title":"Intern Med"},{"key":"2025080115380164900_keaf216-B15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40744-015-0008-9","article-title":"Characteristics associated with biologic monotherapy use in biologic-naive patients with rheumatoid arthritis in a US registry population","volume":"2","author":"Pappas","year":"2015","journal-title":"Rheumatol Ther"},{"key":"2025080115380164900_keaf216-B16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"2025080115380164900_keaf216-B17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan\u2019s National Health Insurance Research Database: past and future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2025080115380164900_keaf216-B18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2147\/CLEP.S426485","article-title":"Cross-regional data initiative for the assessment and development of treatment for neurological and mental disorders","volume":"15","author":"Tsai","year":"2023","journal-title":"Clin Epidemiol"},{"key":"2025080115380164900_keaf216-B19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/joim.13681","article-title":"Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: a multi-centre cohort study","volume":"294","author":"Tong","year":"2023","journal-title":"J Intern Med"},{"key":"2025080115380164900_keaf216-B20","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/ar3260","article-title":"Validation of rheumatoid arthritis diagnoses in health care utilization data","volume":"13","author":"Kim","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025080115380164900_keaf216-B21","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/ar3260","article-title":"Validation of rheumatoid arthritis diagnoses in health care utilization data","volume":"13","author":"Kim","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025080115380164900_keaf216-B22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-020-02310-z","article-title":"Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available","volume":"22","author":"Curtis","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025080115380164900_keaf216-B23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/schbul\/sbs002","article-title":"Effectiveness of sulpiride in adult patients with schizophrenia","volume":"39","author":"Lai","year":"2013","journal-title":"Schizophr Bull"},{"key":"2025080115380164900_keaf216-B24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90233-9","article-title":"Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function","volume":"63","author":"Meikle","year":"1977","journal-title":"Am J Med"},{"key":"2025080115380164900_keaf216-B25","doi-asserted-by":"crossref","first-page":"628548","DOI":"10.3389\/fphar.2021.628548","article-title":"Switching and discontinuation pattern of biologic disease-modifying antirheumatic drugs and tofacitinib for patients with rheumatoid arthritis in Taiwan","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025080115380164900_keaf216-B26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3899\/jrheum.191252","article-title":"Tofacitinib persistence in patients with rheumatoid arthritis: a retrospective cohort study","volume":"48","author":"Fisher","year":"2021","journal-title":"J Rheumatol"},{"key":"2025080115380164900_keaf216-B27","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/MLR.0b013e318041384c","article-title":"Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis","volume":"45","author":"Grijalva","year":"2007","journal-title":"Med Care"},{"key":"2025080115380164900_keaf216-B28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41598-023-50379-8","article-title":"Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study","volume":"14","author":"Martinez-Molina","year":"2024","journal-title":"Sci Rep"},{"key":"2025080115380164900_keaf216-B29","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"2025080115380164900_keaf216-B30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/rheumatology\/41.1.38","article-title":"Rheumatoid arthritis severity scale: a brief, physician-completed scale not confounded by patient self-report of psychological functioning","volume":"41","author":"Bardwell","year":"2002","journal-title":"Rheumatology"},{"key":"2025080115380164900_keaf216-B31","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025080115380164900_keaf216-B32","doi-asserted-by":"crossref","first-page":"e072300","DOI":"10.1136\/bmjopen-2023-072300","article-title":"Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA","volume":"14","author":"Gilbert","year":"2024","journal-title":"BMJ Open"},{"key":"2025080115380164900_keaf216-B33","doi-asserted-by":"crossref","first-page":"e0193489","DOI":"10.1371\/journal.pone.0193489","article-title":"Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD)","volume":"13","author":"Shi","year":"2018","journal-title":"PloS One"},{"key":"2025080115380164900_keaf216-B34","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","article-title":"Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025080115380164900_keaf216-B35","doi-asserted-by":"crossref","first-page":"1345580","DOI":"10.1080\/20016689.2017.1345580","article-title":"Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region","volume":"5","author":"Kal\u00f3","year":"2017","journal-title":"J Mark Access Health Policy"},{"key":"2025080115380164900_keaf216-B36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10067-017-3584-y","article-title":"Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry","volume":"36","author":"Park","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025080115380164900_keaf216-B37","first-page":"395","article-title":"Switching of biologics in RA patients who do not respond to the first biologic","volume":"85","author":"Durez","year":"2018","journal-title":"Elsevier"},{"key":"2025080115380164900_keaf216-B38","doi-asserted-by":"crossref","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis\u2014a nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025080115380164900_keaf216-B39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors affecting therapeutic compliance: a review from the patient\u2019s perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"2025080115380164900_keaf216-B40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","article-title":"Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment","volume":"13","author":"Kalden","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2025080115380164900_keaf216-B41","doi-asserted-by":"crossref","first-page":"e0175207","DOI":"10.1371\/journal.pone.0175207","article-title":"The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study","volume":"12","author":"Moots","year":"2017","journal-title":"PloS One"},{"key":"2025080115380164900_keaf216-B42","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.3390\/jcm12093271","article-title":"Anti-drug antibodies in the biological therapy of autoimmune rheumatic diseases","volume":"12","author":"Pizano-Martinez","year":"2023","journal-title":"J Clin Med"},{"key":"2025080115380164900_keaf216-B43","first-page":"S40","article-title":"The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis","volume":"34","author":"van Riel","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025080115380164900_keaf216-B44","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","article-title":"Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting","volume":"80","author":"Miyazaki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025080115380164900_keaf216-B45","doi-asserted-by":"crossref","first-page":"e001040","DOI":"10.1136\/rmdopen-2019-001040","article-title":"Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB\/IV trial","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2025080115380164900_keaf216-B46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"2025080115380164900_keaf216-B47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf216\/62953177\/keaf216.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4668\/62953177\/keaf216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4668\/62953177\/keaf216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T19:38:15Z","timestamp":1754077095000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/8\/4668\/8116002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4,18]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf216","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,18]]}}}